{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:35:09Z","timestamp":1794072909221,"version":"4.8.0"},"reference-count":25,"publisher":"American Society of Hematology","issue":"2","license":[{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,28]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Patients with hemophilia A can develop antifactor antibodies to factor VIII. The incidence is \u223c30%, and such patients suffer worse morbidity and mortality. The only proven method to eradicate these inhibitors is via immune tolerance induction therapy, which consists of infusing factor VIII concentrates at regular intervals. This approach is effective \u223c65% of the time, leaving at least a third of patients who develop inhibitors with this lifelong problem. Although emicizumab has greatly improved the quality of life of inhibitor patients, eradicating the inhibitor remains an important treatment goal. Animal models have shown the potential for gene therapy to induce tolerance. A recent abstract describing a study in humans demonstrated the potential for successful tolerance induction. This article will describe the rationale for using gene therapy to induce tolerance and provide this author's viewpoint on the importance and possible historic significance of attempting to eradicate inhibitors with this approach.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013000","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T20:33:36Z","timestamp":1729197216000},"page":"265-269","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["Induction of factor VIII tolerance by hemophilia gene transfer to eradicate factor VIII inhibitors"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6013-1254","authenticated-orcid":false,"given":"Guy","family":"Young","sequence":"first","affiliation":[{"name":"Cancer and Blood Disorders Institute, Children\u2019s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"issue":"10040","key":"2025012813361747900_bib1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0140-6736(15)01123-X","article-title":"The past and future of haemophilia: diagnosis, treatments, and its complications","volume":"388","author":"Peyvandi","year":"2016","journal-title":"Lancet"},{"issue":"5","key":"2025012813361747900_bib2","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1046\/j.1537-2995.1989.29589284147.x","article-title":"Disappearance of inhibitor to factor VIII in HIV-infected hemophiliacs with progression to AIDS or severe ARC","volume":"29","author":"Ragni","year":"1989","journal-title":"Transfusion"},{"issue":"7","key":"2025012813361747900_bib3","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/j.1538-7836.2004.00802.x","article-title":"Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX","volume":"2","author":"Lollar","year":"2004","journal-title":"J\u00a0Thromb Haemost"},{"key":"2025012813361747900_bib4","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.3389\/fimmu.2017.01604","article-title":"Innovative approaches for immune tolerance to factor VIII in the treatment of hemophilia A","volume":"8","author":"Sherman","year":"2017","journal-title":"Front Immunol"},{"key":"2025012813361747900_bib5","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.3389\/fimmu.2019.02991","article-title":"Tolerating FVII: recent progress","volume":"10","author":"Lacroix-Desmazes","year":"2019","journal-title":"Front Imunol"},{"issue":"19","key":"2025012813361747900_bib6","doi-asserted-by":"crossref","first-page":"4034","DOI":"10.1182\/blood-2009-06-228155","article-title":"CD4+FoxP3+ regulatory T cells confer long-term regulation of factor VIII-specific immune responses in plasmid-mediated gene-therapy-treated hemophilia mice","volume":"114","author":"Miao","year":"2009","journal-title":"Blood"},{"issue":"7","key":"2025012813361747900_bib7","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1182\/blood-2009-01-200725","article-title":"Lineages of human T-cell clones, including T helper 17\/ T helper 1 cells, isolated at different stages of anti-factor VIII immune responses","volume":"114","author":"Ettinger","year":"2009","journal-title":"Blood"},{"issue":"3","key":"2025012813361747900_bib8","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1182\/blood-2009-03-202267","article-title":"A\u00a0murine model for induction of long-term immunologic tolerance to factor VIII does not require persistent detectable levels of plasma factor VIII and involves contributions from FoxP3+ T regulatory cells","volume":"114","author":"Matsui","year":"2009","journal-title":"Blood"},{"issue":"22","key":"2025012813361747900_bib9","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1182\/blood-2013-01-478669","article-title":"Progress toward inducing immunologic tolerance to factor VIII","volume":"121","author":"Scott","year":"2013","journal-title":"Blood"},{"issue":"16","key":"2025012813361747900_bib10","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the Haven 1-4 studies","volume":"137","author":"Callaghan","year":"2021","journal-title":"Blood"},{"issue":"22","key":"2025012813361747900_bib11","first-page":"2194","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"2025012813361747900_bib12","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1080\/17474086.2018.1531701","article-title":"Emicizumab for hemophilia A with factor VIII inhibitors","volume":"11","author":"Young","year":"2018","journal-title":"Expert Rev Hematol"},{"issue":"8","key":"2025012813361747900_bib13","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa2211075","article-title":"Two year outcomes of valoctocogene roxaparvovec therapy for hemophilia A","volume":"388","author":"Mahlangu","year":"2023","journal-title":"N Eng J Med"},{"issue":"9","key":"2025012813361747900_bib14","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1172\/JCI200316887","article-title":"Induction of immune tolerance to coagulation factor IX by in\u00a0vivo gene transfer","volume":"111","author":"Mingozzi","year":"2003","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"2025012813361747900_bib15","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2174\/156652309787909490","article-title":"Hepatic gene transfer as a means of tolerance induction to transgene product","volume":"9","author":"Loduca","year":"2009","journal-title":"Curr Gene Ther"},{"issue":"6","key":"2025012813361747900_bib16","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/jth.13331","article-title":"Gene therapy for immune tolerance induction in hemophilia with inhibitors","volume":"14","author":"Arruda","year":"2016","journal-title":"J\u00a0Thromb Haemost"},{"issue":"7","key":"2025012813361747900_bib17","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1182\/blood-2007-03-080093","article-title":"Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to the liver","volume":"110","author":"Mingozzi","year":"2007","journal-title":"Blood"},{"issue":"26","key":"2025012813361747900_bib18","doi-asserted-by":"crossref","first-page":"5482","DOI":"10.1182\/blood-2010-06-288001","article-title":"Eradication of neutralizing antibodies to FVIII in canine hemophilia A after liver gene therapy","volume":"116","author":"Finn","year":"2010","journal-title":"Blood"},{"issue":"11","key":"2025012813361747900_bib19","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1002\/emmm.201302859","article-title":"Effective gene therapy for haemophilic mice with pathogenic FIX antibodies","volume":"5","author":"Markusic","year":"2013","journal-title":"EMBO Mol Med"},{"issue":"10","key":"2025012813361747900_bib20","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/blood-2014-07-588194","article-title":"AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice","volume":"125","author":"Crudele","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2025012813361747900_bib21","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1182\/blood-2008-10-181479","article-title":"Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy","volume":"113","author":"Niemeyer","year":"2009","journal-title":"Blood"},{"key":"2025012813361747900_bib22","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3389\/fimmu.2020.00618","article-title":"Translational potential of immune tolerance induction by AAV liver-directed factor VIII gene therapy in hemophilia A","volume":"11","author":"Samelson-Jones","year":"2020","journal-title":"Front Immunol"},{"issue":"11","key":"2025012813361747900_bib23","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1016\/j.jtha.2023.05.011","article-title":"A review of rationale for gene therapy for haemophilia A with inhibitors: one-shot tolerance and treatment?","volume":"21","author":"Valentino","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"S1","key":"2025012813361747900_bib24","first-page":"18","article-title":"Safety and efficacy of valoctocogene roxaparvovec with prophylactic corticosteroids: 1 year GENEr8 3 results","volume":"30","author":"Ozelo","year":"2024","journal-title":"Haemophilia"},{"key":"2025012813361747900_bib25","first-page":"26","article-title":"Safety and efficacy of valoctocogene roxaparvovec in participants with active and prior FVIII inhibitors: preliminary results from the GENEr8-INH, a phase 1\/2 study.","volume":"30","author":"Young","year":"2024","journal-title":"Haemophilia"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/2\/265\/2351544\/blooda_adv-2024-013000-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/2\/265\/2351544\/blooda_adv-2024-013000-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T13:36:38Z","timestamp":1738071398000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/2\/265\/518218\/Induction-of-factor-VIII-tolerance-by-hemophilia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,1,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013000","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,15]]}}}